Main Category: Fibromyalgia
Also Included In: Depression; Psychology / Psychiatry; Arthritis / Rheumatology
Article Date: 22 Nov 2011 – 5:00 PST
email to a friend printer friendly opinions
<!– rate article
Patient / Public:Healthcare Prof:
According to a recent multi-site trial published in Arthritis Rheumatism, a peer-reviewed journal of the American College of Rheumatology (ACR), cognitive-behavioral therapy (CBT) reduces functional disability and depressive symptoms in adolescent with juvenile fibromyalgia. The trial demonstrated that the psychological therapy was safe and effective as well as superior to disease management education.
According to medical evidence approximately 2 to 7% of school-aged children are affected by juvenile fibromyalgia syndrome, which similar as in adults, predominantly affects adolescent girls. The characteristics in both adult and juvenile fibromyalgia patients are widespread musculoskeletal pain, fatigue together with sleep and mood disturbances. Earlier studies have established that juvenile fibromyalgia patients suffer from substantial physical, school, social and emotional impairments. So far, there are only few studies for treating the juvenile form of the disorder.
Study leader Dr. Susmita Kashikar-Zuck from the Division of Behavioral Medicine and Clinical Psychology at Cincinnati Children’s Hospital Medical Center in Ohio and her team decided to investigate fibromyalgia in juveniles and enrolled 114 adolescents who were diagnosed with the disorder between the ages of 11 to 18 years. The trial was carried out at four pediatric rheumatology centers from December 2005 to 2009. Participants were randomized to cognitive-behavioral therapy or fibromyalgia education in form of eight weekly individual therapy sessions and two additional sessions in the six months after completion of the active therapy.
At the end of the trial, the findings demonstrated that both patient groups showed a substantial reduction in functional disability, pain, and depressive symptoms. According to the researchers, pediatric participants in the cognitive-behavioral therapy group displayed a substantially lower functional disability with an improvement of 37% in disability compared with those in the fibromyalgia education group who achieved a 12% disability improvement. At study-end both groups had scored in the non-depressed range, however, pain reduction was clinically insignificant with a decrease in pain of less than 30% in both groups.
More than 85% of the participants attended all therapy sessions, meaning that only few participants dropped out, and researchers reported no study-related adverse events.
Dr. Kashikar-Zuck concludes:
“Our trial confirms that cognitive-behavioral therapy is a safe and effective treatment for reducing functional disability and depression in patients with juvenile fibromyalgia. When added to standard medical care, cognitive-behavioral therapy helps to improve daily functioning and overall wellbeing for adolescents with fibromyalgia.”
Written by Petra Rattue
“A Randomized Clinical Trial of Cognitive Behavioral Therapy for the Treatment of Juvenile Fibromyalgia.”
Susmita Kashikar-Zuck, Tracy V. Ting, Lesley M Arnold, Judy Bean, Scott W. Powers, T. Brent Graham, Murray H. Passo, Kenneth N. Schikler, Philip J. Hashkes, Steven Spalding, Anne M. Lynch-Jordan, Gerard Banez, Margaret M. Richards and Daniel J. Lovell.
Arthritis Rheumatism; Published Online: November 22, 2011 (DOI: 10.1002/art.30644)
Please use one of the following formats to cite this article in your essay, paper or report:
Please note: If no author information is provided, the source is cited instead.
Please note that we publish your name, but we do not publish your email address. It is only used to let
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2011 All rights reserved.